A New Golden Age Of Psychedelic Therapy? Proceed With Caution

By Ben Comer, Chief Editor, Life Science Leader

It was eye-opening for me, as I expect it will be for many readers of Life Science Leader, to learn that the Multidisciplinary Association for Psychedelic Studies (MAPS) aims to dose 1 million post-traumatic stress disorder (PTSD) patients with MDMA by 2031. MDMA, which MAPS founder and executive director Rick Doblin has called the “gentlest” of the psychedelic compounds currently being investigated for therapeutic use, is expected to receive the FDA’s blessing during the first half of 2024, if not sooner.